title: Norepinephrine loss produces more profound motor deficits than MPTP treatment in mice.
abstract: Although Parkinson's disease (PD) is characterized primarily by loss of nigrostriatal dopaminergic neurons, there is a concomitant loss of norepinephrine (NE) neurons in the locus coeruleus. Dopaminergic lesions induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) are commonly used to model PD, and although MPTP effectively mimics the dopaminergic neuropathology of PD in mice, it fails to produce PD-like motor deficits. We hypothesized that MPTP is unable to recapitulate the motor abnormalities of PD either because the behavioral paradigms used to measure coordinated behavior in mice are not sensitive enough or because MPTP in the absence of NE loss is insufficient to impair motor control. We tested both possibilities by developing a battery of coordinated movement tests and examining motor deficits in dopamine beta-hydroxylase knockout (Dbh-/-) mice that lack NE altogether. We detected no motor abnormalities in MPTP-treated control mice, despite an 80% loss of striatal dopamine (DA) terminals. Dbh-/- mice, on the other hand, were impaired in most tests and also displayed spontaneous dyskinesias, despite their normal striatal DA content. A subset of these impairments was recapitulated in control mice with 80% NE lesions and reversed in Dbh-/- mice, either by restoration of NE or treatment with a DA agonist. MPTP did not exacerbate baseline motor deficits in Dbh-/- mice. Finally, striatal levels of phospho-ERK-1/2 and DeltaFosB/FosB, proteins which are associated with PD and dyskinesias, were elevated in Dbh-/- mice. These results suggest that loss of locus coeruleus neurons contributes to motor dysfunction in PD.
authors: Department of Human Genetics, Rollins School of Public Health, Emory University, Atlanta, GA 30322, USA.
authors: K S
authors: KS
authors: Rommelfanger
authors: G L
authors: GL
authors: Edwards
authors: K G
authors: KG
authors: Freeman
authors: L C
authors: LC
authors: Liles
authors: G W
authors: GW
authors: Miller
authors: D
authors: D
authors: Weinshenker
mesh_terms: D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine / Q000494:pharmacology*; D000818:Animals; D001522:Behavior, Animal; D004299:Dopamine beta-Hydroxylase / Q000172:deficiency / Q000235:genetics / Q000378:metabolism; D008125:Locus Coeruleus / Q000378:metabolism; D051379:Mice; D018345:Mice, Knockout; D019950:Mitogen-Activated Protein Kinase 1 / Q000378:metabolism; D048052:Mitogen-Activated Protein Kinase 3 / Q000378:metabolism; D009043:Motor Activity / Q000187:drug effects*; D009638:Norepinephrine / Q000378:metabolism*; D010641:Phenotype; D010766:Phosphorylation; D016760:Proto-Oncogene Proteins c-fos / Q000235:genetics / Q000378:metabolism; D011954:Receptors, Dopamine / Q000378:metabolism
chemical_list: D016760:Proto-Oncogene Proteins c-fos; D011954:Receptors, Dopamine; D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; D004299:Dopamine beta-Hydroxylase; D019950:Mitogen-Activated Protein Kinase 1; D048052:Mitogen-Activated Protein Kinase 3; D009638:Norepinephrine
references: Biol Psychiatry. 2006 Jan 1;59(1):64-74
references: 16139809
references: Psychopharmacology (Berl). 2005 Nov;183(1):72-80
references: 16163519
references: J Neural Transm (Vienna). 2006 Sep;113(9):1119-29
references: 16362627
references: Neuropsychopharmacology. 2006 Oct;31(10):2221-30
references: 16395294
references: Brain Res. 2007 Mar 2;1135(1):219-29
references: 17222394
references: Pharmacol Toxicol. 2000 May;86(5):197-202
references: 10862500
references: Neuroscience. 2000;101(4):1063-9
references: 11113355
references: Am J Hum Genet. 2001 Feb;68(2):515-22
references: 11170900
references: Synapse. 2001 Mar 1;39(3):213-21
references: 11169770
references: Mov Disord. 2001 Jul;16(4):708-13
references: 11481696
references: J Neuropathol Exp Neurol. 2002 May;61(5):413-26
references: 12030260
references: J Neurosci. 2002 Jun 15;22(12):5042-54
references: 12077200
references: Proc Natl Acad Sci U S A. 2002 Oct 15;99(21):13873-7
references: 12370425
references: Exp Neurol. 2002 Nov;178(1):80-90
references: 12460610
references: Neurobiol Aging. 2003 Mar-Apr;24(2):197-211
references: 12498954
references: J Neural Transm (Vienna). 2003 Feb;110(2):183-200
references: 12589577
references: Arch Neurol. 2003 Mar;60(3):337-41
references: 12633144
references: Receptors Channels. 2003;9(5):335-8
references: 14527878
references: Exp Neurol. 2003 Oct;183(2):418-29
references: 14552882
references: Neurobiol Dis. 2003 Nov;14(2):218-28
references: 14572444
references: Exp Neurol. 2003 Nov;184(1):9-13
references: 14637071
references: Am J Physiol Regul Integr Comp Physiol. 2004 Jan;286(1):R108-13
references: 12969876
references: Neuroscientist. 2003 Dec;9(6):455-62
references: 14678578
references: Brain. 2004 Apr;127(Pt 4):888-99
references: 14960500
references: Brain Res Brain Res Rev. 2004 Apr;45(1):38-78
references: 15063099
references: Synapse. 2004 Jun 15;52(4):233-44
references: 15103690
references: Neurobiol Dis. 2004 Jun;16(1):110-23
references: 15207268
references: J Neurosci. 2004 Oct 20;24(42):9434-40
references: 15496679
references: J Neurol Sci. 1976 Jun;28(2):147-57
references: 818342
references: Brain Res Bull. 1983 Jun;10(6):795-804
references: 6616270
references: Brain Res. 1984 Mar 26;296(1):129-38
references: 6424867
references: Life Sci. 1985 Jan 21;36(3):201-6
references: 2857048
references: Brain Res Bull. 1984 Dec;13(6):737-42
references: 6335836
references: Neurosci Lett. 1985 Oct 24;61(1-2):195-200
references: 3878482
references: Res Commun Chem Pathol Pharmacol. 1985 Dec;50(3):435-41
references: 3878557
references: Ann Neurol. 1986 Oct;20(4):449-55
references: 3024555
references: Neurology. 1987 Jan;37(1):42-6
references: 3796837
references: Acta Neuropathol. 1988;75(4):370-6
references: 3259063
references: Res Commun Chem Pathol Pharmacol. 1988 Oct;62(1):93-102
references: 2849789
references: Neuroscience. 1991;41(2-3):507-23
references: 1870701
references: Brain Res. 1991 Oct 25;562(2):216-24
references: 1685341
references: Life Sci. 1992;50(14):995-9
references: 1372673
references: Adv Neurol. 1993;60:600-8
references: 8380528
references: Eur J Pharmacol. 1993 Jun 4;236(3):487-9
references: 7689466
references: Neuroscience. 1993 Sep;56(2):499-511
references: 8247275
references: Nature. 1995 Apr 13;374(6523):643-6
references: 7715704
references: J Immunol. 1995 Nov 15;155(10):4613-20
references: 7594460
references: Cell. 1995 Dec 29;83(7):1197-209
references: 8548806
references: Funct Neurol. 1997 May-Aug;12(3-4):193-8
references: 9218976
references: J Neurochem. 1998 Jun;70(6):2468-76
references: 9603211
references: Brain Res Mol Brain Res. 1998 Jan;53(1-2):41-52
references: 9473580
references: J Pharmacol Exp Ther. 1997 Oct;283(1):100-7
references: 9336313
references: J Neural Transm (Vienna). 1998;105(4-5):349-64
references: 9720967
references: Eur J Pharmacol. 1998 Jul 17;353(1):1-4
references: 9721033
references: J Neurochem. 1999 Apr;72(4):1625-33
references: 10098870
references: J Neurochem. 1959 Oct;4:350-2
references: 13840158
references: J Neurochem. 2004 Dec;91(5):1116-24
references: 15569255
references: J Neurosci. 2005 Feb 23;25(8):2132-7
references: 15728853
references: J Neurosci. 2005 Feb 23;25(8):2157-65
references: 15728856
references: Exp Neurol. 2005 Jul;194(1):66-75
references: 15899244
references: Lancet Neurol. 2006 Jun;5(6):525-35
references: 16713924